Prostate cancer is the second leading cause of cancer death in men in the United States, with an estimated 248,530 new cases and 34,130 deaths expected in 2021. Early detection and diagnosis of prostate cancer is highly important for successful treatment and management. Unfortunately, current screening tests present several limitations due to their low accuracy, invasiveness, and high cost.
Prostate AI Improves Accuracy of Cancer Detection
Bot Image’s ProstatID is a highly accurate tool for active surveillance of prostate cancer, according to their recent press release. The AI-powered tool uses bpMRI with CAD (AI) to interpret MRI scans of the prostate and provide a more accurate detection and diagnosis of prostate cancer. The ProstatID algorithm has a standalone performance of 93.6% accuracy, significantly higher than other screening modalities.
The PSA test, widely used for screening prostate cancer, only shows the concentration of prostate-specific antigen in the blood and can lead to false positives. Digital rectal exams (DREs) detect abnormalities in the rectum, but are only partially accurate due to the location of the cancer. Biopsies are the only way to confirm the presence of cancer, but they are expensive, invasive, and increase the risk of infections.
Avoid the Costly Pitfalls of Prostate Cancer Pathways
ProstatID’s bpMRI with AI interpretation has huge implications for men’s health and healthcare cost savings. Patients with low to intermediate risk of cancer should carefully weigh their treatment timing and options, as treatment can lead to worse outcomes than watching and waiting, according to a recent report of the New England Journal of Medicine.
The cost of prostate cancer diagnosis and treatment is high, with biopsies costing several thousands of dollars per patient. Bot Image’s ProstatID is poised to change the standard of care for prostate cancer screening, detection, and diagnosis, by avoiding the costly pitfalls of current prostate cancer pathways. The AI-powered tool can significantly reduce unnecessary costs and invasiveness of screening procedures, providing a reliable and accurate tool for men’s healthcare.
The Potential of ProstatID to Change the Standard of Care
Prostate cancer detection and diagnosis could soon become more accurate and accessible with Bot Image’s ProstatID. The tool provides a high level of sensitivity, specificity, and accuracy in detecting the location and extent of cancer lesions. With an accuracy rate of 93.6%, ProstatID outperforms other screening methods that are currently available. ProstatID’s accuracy also significantly improves physician performance in prostate cancer diagnosis.
Although the Prostate Screening EpiSwitch test has also shown promising results in detecting prostate cancer, it still cannot reveal the location and extent of the cancer as imaging with AI does. ProstatID’s bpMRI with CAD allows for a non-invasive and accurate detection and diagnosis of prostate cancer, significantly improving the standard of care for prostate cancer screening and diagnosis.
In conclusion, Bot Image’s ProstatID is a game-changing tool for non-invasive and accurate detection and diagnosis of prostate cancer. ProstatID’s bpMRI with CAD interpretation can significantly reduce the invasiveness, costs, and inaccuracies of current prostate cancer pathways. With an accuracy rate of 93.6%, ProstatID is poised to become the new standard of care for prostate cancer screening, detection, and diagnosis.
